Key statistics
52-week range
Open | 0.905 |
---|---|
High | 0.905 |
Low | 0.905 |
Bid | 0.855 |
Offer | 0.89 |
Previous close | 0.91 |
Average volume | 1.19k |
---|---|
Shares outstanding | 80.88m |
Free float | 80.07m |
P/E (TTM) | -- |
Market cap | 79.27m USD |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Nov 21 2024 07:03 GMT.
More ▼
Press releases
- I-Mab to Participate at the Piper Sandler Healthcare Conference
- I-Mab Reports Third Quarter 2024 Results
- I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
- Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
- I-Mab to Release Q3 2024 Financial Results on November 14, 2024
- I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
- I-Mab to Participate at the Truist Securities BioPharma Symposium
- I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
- I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
More ▼